Solo Pace Fusion System (SOLOFUSE1)— 510(k) K252674

Substantially Equivalent

Solo Pace, Inc.

FDA 510(k) clearance K252674 for Solo Pace Fusion System (SOLOFUSE1), Substantially Equivalent on 2026-01-09. Applicant: Solo Pace, Inc..

Clearance details

Applicant: Solo Pace, Inc.
Product code: Code DQX
Advisory panel: Cardiovascular
Date received: 2025-08-25
Decision date: 2026-01-09
Decision: Substantially Equivalent
Clearance type: Traditional
Location: San Francisco, CA, US

Download summary PDF View on FDA.gov ↗

Adverse events under product code DQX

product code DQX

Death: 298
Injury: 4,385
Malfunction: 7,203
Other: 5
Total: 11,891

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.